Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of Zishen Yutai Pills for diminished ovarian reserve
ChiCTR2200062870Phase 2Not yet recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Zishen Yutai Pill in Diminished Ovarian Reserve (DOR) (3 arms), sponsored by Guang'anmen Hospital. Primary endpoint: anti-Mullerian hormone. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
Zishen Yutai Pill
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on ChiCTR2200062870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062870.